论文部分内容阅读
目的探讨长春瑞滨(NVB)联合顺铂(DDP)方案(NP方案)诱导化疗联合同步放化疗治疗局部晚期鼻咽癌的疗效。方法选取2006年1月至2009年12月间收治的鼻咽癌患者186例,采用区段随机分组法分为治疗组(97例)和对照组(89例)。治疗组患者采用NP方案(NVB25 mg/m2,d1、d8;DDP 25 mg/m2,d1~d3)诱导化疗2个周期后,进行常规分割放疗(总剂量70~76 Gy分35~38次)同步NP方案化疗2个周期;对照组患者仅采用常规分割放疗(总剂量70~76 Gy分35~38次)同步NP方案化疗2个周期。疗程结束后,对两组患者疗效和不良反应进行比较。结果治疗组患者有效率为100.0%,对照组则为96.6%,差异无统计学意义(2=3.323,P>0.05);治疗组患者1年生存率、1年无进展生存率、5年生存率和5年无进展生存率分别为100.0%、97.9%、68.0%和60.8%,均高于对照组的94.4%、89.9%、50.6%和41.6%,差异有统计学意义(均P<0.05)。两组患者不良反应无明显差别(P>0.05)。结论 NP方案诱导化疗联合同步放化疗临床疗效好,耐受性好,值得进一步研究。
Objective To investigate the curative effect of vinblastine combined with cisplatin (NPDP) chemotherapy and concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Methods 186 patients with nasopharyngeal carcinoma admitted between January 2006 and December 2009 were randomly divided into treatment group (97 cases) and control group (89 cases). The patients in the treatment group were treated with conventional radiotherapy (total dose 70-76 Gy 35-38 times) after 2 cycles of induction chemotherapy with NP regimen (NVB25 mg / m2, d1, d8, DDP 25 mg / m2, d1- The patients in the control group were treated with concurrent radiotherapy (total dose of 70-76 Gy, 35-38 times) and concurrent NP regimen for 2 cycles. After treatment, the efficacy and adverse reactions of the two groups were compared. Results The effective rate was 100.0% in the treatment group and 96.6% in the control group, with no significant difference (2 = 3.323, P> 0.05). The 1-year survival rate, 1-year progression-free survival rate and 5 years The survival rates and 5-year progression-free survival rates were 100.0%, 97.9%, 68.0% and 60.8%, respectively, which were significantly higher than 94.4%, 89.9%, 50.6% and 41.6% of the control group (all P < 0.05). Adverse reactions between the two groups showed no significant difference (P> 0.05). Conclusion NP chemotherapy induction chemotherapy combined with concurrent chemoradiotherapy has good curative effect and good tolerance, which deserves further study.